Study of BHV-4157 in Alzheimer's Disease
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT03605667
- Locations
- 🇺🇸
Northern Light Acadia Hospital, Bangor, Maine, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- ALSAmyotrophic Lateral SclerosisLou Gehrig DiseaseLou Gehrig's DiseaseMotor Neuron Disease, Amyotrophic Lateral SclerosisLou-Gehrigs Disease
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Registration Number
- NCT03537807
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1
Completed
- Conditions
- Lou Gehrig's DiseaseAmyotrophic Lateral SclerosisALSLou Gehrig DiseaseLou-Gehrigs DiseaseMotor Neuron Disease, Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03520517
- Locations
- 🇺🇸
Wesley Neurology Clinic, Cordova, Tennessee, United States
🇺🇸Holy Cross Neuroscience Research Institute, Fort Lauderdale, Florida, United States
🇺🇸Texas Neurology, Dallas, Texas, United States
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
Phase 2
Active, not recruiting
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT03299166
- Locations
- 🇺🇸
CalNeuro Research Group, Los Angeles, California, United States
🇺🇸Desert Valley Research, Rancho Mirage, California, United States
🇺🇸Gulfcoast Clinical Research Center, Fort Myers, Florida, United States
Trial in Adult Subjects With Spinocerebellar Ataxia
Phase 2
Completed
- Conditions
- Spinocerebellar Ataxia Genotype Type 6Spinocerebellar Ataxia Genotype Type 8Spinocerebellar Ataxia Genotype Type 1Spinocerebellar Ataxia Genotype Type 2Spinocerebellar AtaxiasSpinocerebellar Ataxia Genotype Type 3Spinocerebellar Ataxia Genotype Type 7Spinocerebellar Ataxia Genotype Type 10
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT02960893
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath